Pharmacodynamics and pharmacokinetcis of micafungin in adults, children and neonate;Farmacodinamia y farmacocinética de la micafungina en adultos, niños y neonatos

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 23-34

  Catalán González, Mercedes ^a   Carlos Montejo González, Juan ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Micafungin; Pharmacodynamics; Pharmacokinetics; Safet

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CYTOCHROME P450; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ANEMIA; ANOREXIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANXIETY; AREA UNDER THE CURVE; ASPERGILLUS; BRADYCARDIA; CANDIDA; CANDIDA ALBICANS; CELL WALL; CHILD; CHOLESTASIS; CONFUSION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; EOSINOPHILIA; ERYTHEMA; FUNGAL CELL; HEART PALPITATION; HEPATITIS; HEPATOMEGALY; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IN VITRO STUDY; INSOMNIA; INVASIVE CANDIDIASIS; JAUNDICE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NAUSEA; NEUTROPENIA; NEWBORN; NONHUMAN; PANCYTOPENIA; PHARMACODYNAMICS; PHLEBITIS; PRURITUS; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT INDICATION; URTICARIA; VOMITING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; BIOTRANSFORMATION; CANDIDA; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ECHINOCANDINS; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; INFANT, NEWBORN; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR STRUCTURE; MYCOSES; PNEUMOCYSTIS JIROVECII; YOUNG ADULT;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS;

EID: 67650732888     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70005-1     Document Type: Review

References (141)

1. Almirante B., and Rodríguez D. Antifungal agents in neonates. Issues and recommendations. Pediatr Drugs 9 (2007) 311-321
2. Arrieta A.C., Telles Filho F., and Berezin E. A randomized, double blind trial comparing micafungin (mcfg) and liposomal amphotericin b (l-amb) in pediatric patients with invasive candidiasis. San Francisco, 46th ICAAC (2006) Abstract n.°: M- 1308b
3. Azuma J., Yamamoto I., Ogura M., Mukai T., Suematsu H., and Kageyama H. Phase I study of FK463, new antifungal agent, in healthy adult male volunteers. San Diego, 38th ICAAC (1998) Abstract n.°: F-146
4. Barnes P.D., and Marr K.A. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin N Am 20 (2006) 545-561
5. Barrett D. From natural products to clinically useful antifungals. Biochim Biophysica Acta 1587 (2002) 224-233
6. Bartizal K., Gill C.J., Abruzzo G.K., Flattery A.M., Kong L., Scott P.M., Smith J.G., Leighton C.E., Bouffard A., Dropinski J.F., and Balkovec J. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother 41 (1997) 2326-2332
7. Benjamin Jr. D.K., Smith P.B., Arrieta A., Castro L., Sanchez P., Kaufman D., Arnold L., Kovanda L., Sawamoto T., Buell D.N., Hope W.W., and Walsh T.J. Safety and Pharmacokinetics (PK) of repeat-dose Micafungin (MICA) in Neonates. Washington, 48th ICAAC (2008) Abstract n.°: A012
8. Betts R.F., Rotstein C., and Talwar D. Comparison of micafungin and caspofungin for candidemia or invasive candidiasis. San Francisco, 46th ICAAC (2006) Abstract n.°: M- 1308a
9. Black K.E., and Baden L.R. Fungal Infections of the CNS Treatment strategies for the immunocompromised Patient. Drugs 21 (2007) 293-318
10. Böhme A., Ruhnke M., Buchheidt D., Cornely O.A., Einsele H., Enzensberger R., Hebart H., Heinz W., Junghanss C., Karthaus M., Krüger W., Krug U., Kubin T., Penack O., Reichert D., Reuter S., Silling G., Südhoff T., Ullmann A.J., and Maschmeyer G. Treatment of invasive fungal infections in cancer patients-Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 88 (2009) 97-110
11. Boucher H.W., Groll A.H., Chiou C.C., and Walsh T.J. Newer Systemic Antifungal Agents. Pharmacokinetics, Safety and Efficacy. Drugs 64 (2004) 1997-2020
12. Bowman J.C., Hicks P.S., Kurtz M.B., Rosen H., Schmatz D.M., Liberator P.A., and Douglas C.M. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46 (2002) 3001-3012
13. Buell D., Kovanda L., and Drake T. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Washington, 45th ICAAC (2005) Abstract n.°: M-719
14. Carrillo-Muñoz A.J., Giusiano G., Ezkurra P.A., and Quindós G. Antifungal agents: Mode of action in yeast cells. Rev Esp Quimioter 19 (2006) 130-139
15. Carver P.L. Micafungin. Ann Pharmacother 38 (2004) 1707-1721
16. Chandrasekar P.H., and Sobel J.D. Micafungin: A New Echinocandin Clin Infect Dis 42 (2006) 1171-1178
17. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., and Walsh T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 45 (2001) 3310-3321
18. Cornely O.A., Böhme A., Buchheidt D., Einsele H., Heinz W.J., Karthaus M., Krause S.W., Krüger W., Maschmeyer G., Penack O., Ritter J., Ruhnke M., Sandherr M., Sieniawski M., Vehreschild J.J., Wolf H.H., and Ullmann A.J. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 94 (2009) 113-122
19. Cross S.A., and Scott L.J. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs 68 (2008) 2225-2255
20. Frattarelli D.A.C., Reed M.D., Giacoia G.P., and Aranda J.V. Antifungals in systemic neonatal candidiasis. Drugs 64 (2004) 949-968
21. De Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della Negra M., and Diekmann-Berndt H. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39 (2004) 842-849
22. De Wet N.T., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M., Ticona E., Llanos E.A., Fisco C., Lau W., and Buell D. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21 (2005) 899-907
23. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., Ullmann A.J., Seibel N.L., Flynn P.M., van Burik J.A., Buell D.N., and Patterson T.F. Micafungin (FK463) alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349
24. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
25. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., and Klepser M.E. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 46 (2002) 3846-3853
26. Eschenauer G., DePestel D.D., and Carver P.L. Comparison of echinocandin antifungals. Ther Clin Risk Manag 3 (2007) 71-97
27. Espinel-Ingrof T.A. Mechanisms of resistance to antifungal agents: Yeasts and filamentous fungi. Rev Iberoam 25 (2008) 101-106
28. Flynn P.M., Seibel N., and Arrieta A. Treatment of invasive aspergillosis (ia) in pediatric patients (pts) with micafungin (mica) alone or in combination with other systemic antifungal agents. San Francisco, 46th ICAAC (2006) Abstract n.°: M-891
29. Fromtling R.A. Micafungin sodium (FK- 463). Drugs Today 38 (2002) 245-257
30. Ikeda F., Tanaka S., Ohki H., Matsumoto S., Maki K., Katashima M., Barrett D., and Aoki Y. Role of Micafungin in the antifungal armamentarium. Curr Med Chem 14 (2007) 1263-1275
31. Gafter-Gvili A., Vidal L., Goldberg E., Leibovici L., and Paul M. Treatment of invasive candidal infections: systematic review and meta-analysis. Mayo Clin Proc 83 (2008) 1011-1021
32. Georgopapadakou N.H. Update on antifungals targeted to the cell wall: focus on beta-1, 3-glucan synthase inhibitors. Expert Opin Investig. Drugs 10 (2001) 269-280
33. Groll A.H., Mickiene D., Petraitiene R., Petraitis V., Lyman C.A., Bacher J.S., Piscitelli S.C., and Walsh T.J. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 45 (2001) 2845-2855
34. Groll A.H., Mickiene D., Petraitis V., Petraitiene R., Ibrahim K.H., Piscitelli S.C., Bekersky I., and Walsh T.J. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antitimicrob Agents Chemother 45 (2001) 3322-3327
35. Groll A.H., Stergiopoulou T., Roilides E., and Walsh T.J. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 14 (2005) 489-509
36. Groll A.H., and Walsh T.J. FK-463 Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti-Infect Invest Drugs 2 (2000) 405-412
37. Gumbo T., Hiemenz J., Ma L., Keirns J.J., Buell D.N., and Drusano G.L. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 60 (2008) 329-331
38. Hashino S., Morita L., Takahata M., Onozawa M., Nakagawa M., Kawamura T., Fujisawa F., Kahata K., Izumiyama K., Yonezumi M., Chiba K., Kondo T., and Asaka M. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 87 (2008) 91-97
39. Hatano K., Morishita Y., Nakai T., and Ikeda F. Antifungal mechanism of FK463 against Candida alb icans and Aspergillus fumigatus. J Antibiot (Tokyo) 55 (2002) 219-222
40. Hebert M.F., Blough D.K., Townsend R.W., Allison M., Buell D., Keirns J., and Bekersky I. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45 (2005) 1018-1024
41. Hebert M.F., Smith H.E., Marbury T.C., Swan S.K., Smith W.B., Townsend R.W., Buell D., Keirns J., and Bekersky I. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45 (2005) 1145-1152
42. Hebert M.F., Townsend R.W., Austin S., Balan G., Blough D.K., Buell D., Keirns J., and Bekersky I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45 (2005) 954-960
43. Hector R.F. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 6 (1993) 1-21
44. Heresi G.P., Gerstmann D.R., Reed M.D., Van den Anker J.N., Blumer J.L., Kovanda L., Keirns J.J., Buell D.N., and Kearns G.L. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 25 (2006) 1110-1115
45. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., Lau W., Facklam D., and Buell D. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 49 (2005) 1331-1336
46. Hiemenz J., Cagnoni P., Simpson D., Devine S., and Chao N. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. 39th ICAAC. San Francisco (1999) Abstract n.° 1648
47. Hiemenz J., Cagnoni P., and Simpson D. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients. 39th ICAAC. San Francisco (1999) Abstract n. ° 576
48. Hiramatsu Y., Maeda Y., Fujii N., Saito T., Nawa Y., Hara M., Yano T., Asakura S., Sunami K., Tabayashi T., Miyata A., Matsuoka K.I., Shinagawa K., Ikeda K., Matsuo K., Tanimoto M., and For the West-Japan Hematology and Oncology Group (West-JHOG). Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 88 (2008) 588-595
49. Hirata K., Aoyama T., Matsumoto Y., Ogawa F., Yamazaki H., Kikuti A., and Yamamoto Y. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 127 (2007) 897-901
50. Hope W.W., Mickiene D., Petraitis V., Petraitiene R., Kelaher A.M., Hughes J.E., Cotton M.P., Bacher J., Keirns J.J., Buell D., Heresi G., Benjamin Jr. D.K., Groll A.H., Drusano G.L., and Walsh T.J. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 197 (2008) 163-171
51. Hope W.W., Seibel N.L., Schwartz C.L., Arrieta A., Flynn P., Shad A., Albano E., Keirns J.J., Buell D.N., Gumbo T., Drusano G.L., and Walsh T.J. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 51 (2007) 3714-3719
52. Ikeda F., Saika T., Sato Y., Suzuki M., Hasegawa M., Mikawa T., Kobayashi I., and Tsuji A. Antifungal activity of micafungin against Candida spp and Aspergillus spp. isolated from pediatric patients in Japan. Med Mycol 31 (2008) 1-4
53. Ikeda F., Tanaka S., Ohki H., Matsumoto S., Maki K., Katashima M., Barrett D., and Aoki Y. Role of micafungin in the antifungal armamentarium. Curr Med Chem 14 (2007) 1263-1275
54. Izumikawa K., Ohtsu Y., Kawabata M., Takaya H., Miyamoto A., Sakamoto S., Kishi K., Tsuboi E., Homma S., and Yoshimura K. Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 45 (2007) 273-278
55. Jarvis B., Figgitt D.P., and Scott L.J. Micafungin. Drugs 64 (2004) 969-982
56. Johnson E.M., Goldstein B.P., Davey K.G., and Fraser M.A. Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole against a panel of 780 yeasts obtained from five European centres. Prague, 14th European Congress of Clinical Microbiology and Infectious Diseases (2004) Poster n.° 513
57. Joseph J.M., Jain R., and Danziger L.H. Micafungin: a new echinocandin antifungal. Pharmacotherapy 27 (2007) 53-67
58. Karthaus M., and Cornely O.A. Treatment options in candidaemia. Mycoses 50 Suppl 1 (2007) 44-49
59. Keirns J., Sawamoto T., Holum M., Buell D., Wisemandle W., and Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51 (2007) 787-790
60. Kim R., Khachikian D., and Reboli A.C. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 8 (2007) 1479-1492
61. Kishino S., Ohno K., Shimamura T., and Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 18 (2004) 676-680
62. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., Niki Y., and Ikemoto H. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36 (2004) 372-379
63. Kohno S., Masaoka T., and Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycosis in Japan. Chicago, 41st ICAAC (2001) Abstract n.° J-834
64. Kubiak D.W., Bryar J.M., McDonnell A.M., Delgado-Flores J.O., Mui E., Baden L.R., and Marty F.M. Evaluating the conversion of caspofungiun (CAS) to micafungina (MIC) as empiric antifungal therapy in patients with persistent fever and neutropenia. Washington, 48th ICAAC (2008) Abstract n.° M2168
65. Kurtz M.B., and Douglas C.M. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 35 (1997) 79-86
66. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H., Cornely O.A., and Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
67. Laverdiere M., Hoban D., Restieri C., and Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50 (2002) 119-123
68. Lóránd T., and Kocsis B. Recent Advances in antifungal agents. Mini Rev Med Chem 7 (2007) 900-911
69. Maesaki S., Hossain M.A., Miyazaki Y., Tomono K., Tashiro T., and Kohno S. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 44 (2000) 1728-1730
70. Manavathu E.K., Ganesan L.T., and Cutright P.H. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B. Chicago, 41st ICAAC (2001) Abstract n.° J-125
71. Manavathu E.K., Ramesh M.S., Baskaran I., Ganesan L.T., and Chandrasekar P.H. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 53 (2004) 386-389
72. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
73. Maschmeyer G., Haas A., and Cornely O.A. Invasive Aspergillosis. Epidemiology, diagnosis and management in immunocompromised patients. Drugs 67 (2007) 1567-1601
74. Metcalf S.C., and Dockrell D.H. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 55 (2007) 287-299
75. Mikamo H., Sato Y., and Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 46 (2000) 485-487
76. Moore C.B., and Denning D.W. Tolerance and fungicidality in vitro of caspofungin, micafungin and anidulafungin against Candida guilliermondii. San Diego, 42nd ICAAC (2002) Abstract n.° M-230
77. Moudgal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 (2005) 767-769
78. Mukai T., Ohkuma T., Nakahara K., Takaya T., Uematsu T., and Azuma J. Pharmacokinetics of FK463, a novel echinocandin analogue, in elderly and non-elderly subjects). Chicago, 41st ICAAC (2001) Abstract n.° A-30
79. Muller F.M., Kurzai O., Hacker J., Frosch M., and Muhlschlegel F. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 48 (2001) 713-715
80. Nakai T., Uno J., Ikeda F., Tawara S., Nishimura K., and Miyaji M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 47 (2003) 1376-1381
81. Nakai T., Uno J., Otomo K., Ikeda F., Tawara S., Goto T., Nishimura K., and Miyaji M. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48 (2002) 78-81
82. Nakai T., Watabe E., Otomo K., Hatano K., and Ikeda F. In vitro pharmacodynamic characterization of micafungin against 5 different Candida species. San Diego, 42nd ICAAC (2002) Abstract n.° A-494
83. Nakagawa Y., Ichii Y., Saeki Y., Kodaka M., Suzuki K., and Kishino S. Plasma concentration of micafungin in patients with hematologic malignancies. J Infect Chemother 13 (2007) 39-45
84. Nicasio A.M., Tessier P.R., Shore E., Russomanno J., Knauft R.F., Nicolau D.P., and Kuti J.L. Bronchopulmoanry Pharmacokinetics (PK) of Micafungin (MICA) in healthy adult volunteers. Washington, 48th ICAAC (2008) Abstract n.° A010
85. Nishiyama Y., Uchida K., and Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin- like lipopeptide. J Electron Microsc (Tokyo) 51 (2002) 247-255
86. Niwa T., Shiraga T., and Takagi A. Drug-drug interaction of antifungal drugs. Yakugaku Zasshi 125 (2005) 795-805
87. O'Shaughnessy E.M., Peter J., and Walsh T.J. In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus. San Diego, 42nd ICAAC (2002) Abstract n.° M-856
88. Okugawa S., Ota Y., Tatsuno K., Tsukada K., Kishino S., and Koike K. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 39 (2007) 344-346
89. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., Lipton J., Jacobs P., van Rensburg J.H., Rex J.H., Lau W., Facklam D., and Buell D.N. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661
90. Ostrosky-Zeichner L., Matar M., and Paetznick V.L. In-vitro synergy testing of anidulafungin (AFG) and micafungin 30. (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. San Diego, 42nd ICAAC (2002) Abstract n.° M-1816.
91. Ostrosky-Zeichner L., Paetznick V.L., Mohr J., Rodriguez J.R., Chen E., and Sancak B. In vitro antifungal activity of FK- 463 against Candida spp. Toronto, 40th ICAAC (2000) Abstract n.° 197
92. Ostrosky-Zeichner L., Paetznick V.L., Sancak B., Rodriguez J.R., Chen E., and Rex J.H. Correlation of minimum inhibitory concentrations (MIC) and disk diffusion inhibition diameters (DDID) for FK- 463 in 403 blood stream isolates of Candida spp. Chicago, 41st ICAAC (2001) Abstract n.° J-572
93. Ostrosky-Zeichner L., and Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 34 (2006) 857-863
94. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., Powderly W.G., Hyslop N., Kauffman C.A., Cleary J., Mangino J.E., and Lee J. Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
95. Ota S., Tanaka J., Kahata K., Toubai T., Kondo K., Mori A., Toyoshima N., Musashi M., Asaka M., and Imamura M. Successful micafungin (fk463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol 79 (2004) 390-393
96. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., Vazquez J.A., Dupont B.F., Horn D.L., Ostrosky-Zeichner L., Reboli A.C., Suh B., Digumarti R., Wu C., Kovanda L.L., Arnold L.J., and Buell D.N. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
97. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10 (2007) 121-130
98. Petraitiene R., Petraitis V., Groll A.H., Candelario M., Sein T., Bell A., Lyman C.A., McMillian C.L., Bacher J., and Walsh T.J. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 43 (1999) 2148-2155
99. Petraitiene R., Petraitis V., Groll A.H., Sein T., Schaufele R.L., Francesconi A., Bacher J., Avila N.A., and Walsh T. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 46 (2002) 12-23
100. Petraitis V., Petraitiene R., Groll A.H., Roussillon K., Hemmings M., Lyman C.A., Sein T., Bacher J., Bekersky I., and Walsh T.J. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 46 (2002) 1857-1869
101. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., Sein T., Groll A.H., Bacher J., Avila N.A., and Walsh T.J. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 187 (2003) 1834-1833
102. Pettengell K., Mynhardt J., Kluyts T., Lau W., Facklam D., Buell D., and FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 20 (2004) 475-481
103. Pettengell K., Mynhardt J., Kluyts T., Simjee A., and Baraldi E. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients. Toronto, 40th ICAAC (2000) Abstract n.° 371
104. Pfaller M.A., Messer S.A., Hollis R.J., and Jones R.N. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3, 685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 45 (2001) 2862-2864
105. Powles R., Sirohi B., Chopra R., Russel N., and Prentice H.G. Assessment of maximum tolerated dose (MTD) of FK463 in cancer patients undergoing haematopoietic stem cell transplantation Chicago. 41st ICAAC (2001) Abstract n.° J-676
106. Powles R., Sirohi B., Chopra R., Russel N., and Prentice H.G. Use of FK 463, a novel echinocandin analog in patients undergoing autologous or allogeneic stem cell transplantation for haematologic malignancies, a matched pair comparison of biochemical toxicity with historical controls (abstract 867-I). Blood 98 (2001) 867
107. Queiroz-Telles F., Berezin E., Leverger G., Freire A., Van der Vyver A., Chotpitayasunondh T., Konja J., Diekmann-Berndt H., Koblinger S., Groll A.H., Arrieta A., and Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27 (2008) 820-826
108. Ratanatharathorn V., Flynn P., Van Burik J.A., McSweeney P., Niederwieser D., and Kontoyiannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients. Philadelphia, 44th Annual American Society of Hematology meeting (2002) Abstract n. 722
109. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., Loebenberg D., Black T.A., and McNicholas P.M. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
110. Seibel N., Schwartz C., Arrieta A., Flynn P., Shad A., and Albano E. A Phase 1 study to determine the safety and pharmacokinetics (pk) of FK463 (echinocandin) in febrile neutropenic pediatric patients. Toronto, 40th ICAAC (2000) Abstract n.° 18
111. Seibel N.L., Schwartz C., Arrieta A., Flynn P., Shad A., Albano E., Keirns J., Lau W.M., Facklam D.P., Buell D.N., and Walsh T.J. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 49 (2005) 3317-3324
112. Serena C., Ortoneda M., Capilla J., Pastor F.J., Sutton D.A., Rinaldi M.G., and Guarro J. In vitro activities of new antifungal agents against Chaetomium spp. and inoculums standardization. Antimicrob Agents Chemother 47 (2003) 3161-3164
113. Sheng-Yuan Ruan, Chen-Chen ChuX, and Po-Ren Hsueh. In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible- dose dependent Candida glabrata isolates. Antimicrob Agents Chemother 52 (2008) 2919-2922
114. Steinbach W.J., and Benjamin D.K. New antifungal agents under development in children and neonates available data in pediatric and neonatal patients. Curr Opin Infect Dis 18 (2005) 484-489
115. Stevens D.A. Susceptibility to micafungin (M) of isolates from clinical trials. San Diego, 42nd ICAAC (2002) Abstract n.° M-1520
116. Suzuki T., Uno T., Chen G., and Ohashi Y. Ocular distribution of intravenously administered micafungin in rabbits. J Infect Chemother 14 (2008) 204-207
117. Takakura S., Fujihara N., Saito T., Kudo T., Iinuma Y., and Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53 (2004) 283-289
118. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., Goto T., Tomishima M., Ohki H., Yamada A., Kawabata K., Takasugi H., Sakane K., Tanaka H., Matsumoto F., and Kuwahara S. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44 (2000) 57-62
119. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 23 (2004) 805-812
120. Townsend R., Bekersky I., and Buell D.N. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients. Washington, 11th Focus on Fungal Infections Meeting (2001) Abstract n.° 024
121. Townsend R., Hebert M., Wisemandle W., and Bekersky I. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers (abstract 15). J Clin Pharmacol 42 (2002) 1055
122. Townsend R., Hebert M., and Wisemandle W. Concomitant pharmacokinetics (PK) of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers [abstract]. Proceedings of the 31st Annual Meeting of the American College of Clinical Pharmacology. 2002 Sep 21-23; San Francisco. J Clin Pharmacol (2002) 1055 42
123. Townsend R., Terakawa M., and Bekersky I. Pharmacokinetics of FK463, a novel echinocandin antifungal, in bone marrow or peripheral stem cell transplant patients abstract. J Clin Pharmacol 40 (2000) 1049
124. Townsend R., Terakawa M., and Bekersky I. PK/disposition of 14C/ FK463, a novel echinocandin antifungal, in male volunteers abstract. J Clin Pharmacol 40 (2000) 1048
125. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., and Gaynes R.P. Secular trend of hospitalacquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
126. Uchida K., Nishiyama Y., Yokota N., and Yamaguchi H. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. J Antibiot (Tokyo) 53 (2000) 1175-1181
127. Ullmann A.J., Van Burik J.A., and McSweeney P. An open phase II study of the efficacy of micafungin (FK463) alone and in combination for the treatment of invasive aspergillosis (IA) in adults and children. Glasgow, 13th European Congress of Clinical Microbiology and Infectious Diseases (2003) Abstract n.° 722
128. Van Burik J.A. Role of new antifungal agents in prophylaxis of mycoses in high risk patients. Curr Opin Infect Dis 18 (2005) 479-483
129. Van Burik J., Ratanatharathorn V., Lipton J., Miller C., Bunin N., and Walsh T.J. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing haematopoetic stem cell transplant. San Diego 42nd ICAAC (2002) Abstract n.° M-1238
130. Van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., Walsh T.J., and National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
131. Van Wart S.A., Iyer V., Forrest A., Bhavnani S.M., Ambrose P.G., and Andes D.R. Population pharmacokinetics (PPK) of Micafungin (MICA) in patients with invasive candidisis, candidemia and esophageal candidiasis. Washington, 48th ICAAC (2008) Abstract n.° A011
132. Vehreschild J.J., and Cornely O.A. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol 1 (2006) 161-170
133. Wagner C., Graninger W., Presterl E., and Joukhadar C. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78 (2006) 161-177
134. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., Morrison V.A., Segal B.H., Steinbach W.J., Stevens D.A., van Burik J.A., Wingard J.R., and Patterson T.F. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
135. Watabe E., Nakai T., Matsumoto S., Ikeda F., and Hatano K. Antimicrob. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 47 (2003) 1995-1998
136. Wiederhold N.P., and Lewis II J.S. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 8 (2007) 1155-1166
137. Steinbach W.J., and Benjamina D.K. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 18 (2005) 484-489
138. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., Baba H., Emi N., and Naoe T. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45 (2006) 259-264
139. Yokote T., Akioka T., Oka S., Fujisaka T., Yamano T., Hara S., Tsuji M., and Hanafusa T. Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol 83 (2004) 64-66
140. Zaoutis T., and Walsh T.J. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis 20 (2007) 592-597
141. Zhanel G.G., Karlowsky J.A., Harding G.A., Balko T.V., Zelenitsky S.A., Friesen M., Kabani A., Turik M., and Hoban D.J. In vitro activity of a new semisynthetic echinocandin, LY- 303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 41 (1997) 863-865